Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

European Medical Group Changes Drug Data-Release Policy After Criticism

share with twitter share with LinkedIn share with facebook
share via e-mail
03/22/2012 | 06:28pm CET
   By Peter Loftus 

A European medical society has changed its plans for releasing results of clinical studies of liver-disease therapies after some critics said the original plan would have amounted to selective disclosure to certain investors.

The studies are expected to include potentially market-moving results of trials involving hepatitis C drugs in development at Abbott Laboratories (>> Abbott Laboratories), Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.) and Gilead Sciences Inc. (GILD).

The European Association for the Study of the Liver now plans to publicly release summaries of most of the studies online April 4, two weeks ahead of the association's International Liver Congress meeting in Barcelona.

Under the new policy, certain studies selected to be highlighted by EASL's press office won't be made available publicly until the date and time of their presentation at the conference, which runs April 18-22. EASL didn't say which studies will be selected. However, EASL said they won't be made available in advance to non-media conference participants before the embargoes lift.

Previously, EASL had planned to make the summaries available online Thursday, but only accessible to EASL members and those registered for the conference, which includes analysts and investors. EASL also previously planned to prohibit media registered to attend the conference from reporting on the summaries until the conference.

Critics of the policy, including TheStreet.com reporter Adam Feuerstein, said the original plans amounted to selective disclosure by providing material information to people who paid to attend the conference, while unfairly leaving others in the dark.

"EASL is making these changes in light of recent criticism of its proposed policy, which suggests that 'selective distribution' of officially accepted clinical data in advance of the Congress would make our proposed embargo policy untenable," EASL said in a written statement Thursday.

The presentation of drug data at medical meetings has long posed a conundrum for companies and investors. Some conferences have made changes in their policies to address concerns.

The American Society of Clinical Oncology, for instance, used to distribute study summaries to participants at its annual meeting weeks ahead of the conference, but prohibit media from reporting the contents until the conference.

ASCO has since changed its policy so that now most summaries are posted publicly online a few weeks before the annual scientific meeting, while certain featured studies aren't publicly disclosed until the meeting.

Scott Gottlieb, a physician and resident fellow at the American Enterprise Institute who has criticized certain medical meeting embargo policies, said EASL did the right thing.

"I think the days of conferences engaging in selective release of important study results are probably over," he said. "ASCO yielded to this truth, EASL did, and I suspect other major conferences will be that much more reluctant to now buck these precedents."

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; [email protected]

Stocks mentioned in the article : Abbott Laboratories, Bristol Myers Squibb Co.
Stocks mentioned in the article
ChangeLast1st jan.
ABBOTT LABORATORIES 0.63% 62.65 Delayed Quote.10.71%
BRISTOL-MYERS SQUIBB COMPANY 0.54% 66.43 Delayed Quote.7.82%
GILEAD SCIENCES -0.34% 76.92 Delayed Quote.7.37%
share with twitter share with LinkedIn share with facebook
share via e-mail
03/19ABBOTT : 's MitraClip Therapy Receives National Reimbursement in Japan to Treat ..
03/16GLOBAL MARKET OVERVIEW FOR MEDICAL M : Research details developments in the Glob..
03/16Drug Makers Use Nanotechnology to Improve Delivery and Dosing
03/15ABBOTT LABORATORIES : Trademark Application for "LUVOX" Filed by Abbott Laborato..
03/15ABBOTT LABORATORIES : An Application for the Trademark "TNI-NX" Has Been Filed b..
03/15ABBOTT LABORATORIES : Patent Issued for Accelerated Wright-Giemsa and may-Grunwa..
03/15ABBOTT LABORATORIES : Patent Application Titled "Nutritional Formulations Includ..
03/15ABBOTT LABORATORIES : Trademark Application for "APTIVUE" Filed by Abbott Labora..
03/15ABBOTT LABORATORIES : New long-term data show improved survival and lower rates ..
03/14ABBOTT LABORATORIES : `s HeartMate 3 pump shows improved results in clinical tri..
More news
News from SeekingAlpha
03/20FDA Ad Com tomorrow for reclassification of certain laboratory devices used i.. 
03/19ABBOTT LABORATORIES : Nutritionally Unhealthy? 
03/16Key events next week - healthcare 
03/15Cintas Is A Great Operator - Cramer's Lightning Round (3/14/18) 
03/12Abbott HeartMate 3 shows treatment benefit in large-scale study 
Financials ($)
Sales 2018 30 853 M
EBIT 2018 6 453 M
Net income 2018 3 041 M
Debt 2018 14 765 M
Yield 2018 1,79%
P/E ratio 2018 40,35
P/E ratio 2019 33,35
EV / Sales 2018 4,00x
EV / Sales 2019 3,67x
Capitalization 109 B
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 68,2 $
Spread / Average Target 9,5%
EPS Revisions
Miles D. White Chairman & Chief Executive Officer
Brian B. Yoor Chief Financial Officer & Executive VP-Finance
Randel W. Woodgrift VP-Abbott Medical Devices Cardiovascular
Roxanne Schuh Austin Independent Director
Jim Farrell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-4.32%358 615
PFIZER1.55%218 946
NOVARTIS-6.12%214 541
ROCHE HOLDING LTD.-11.01%199 453
MERCK AND COMPANY-2.91%150 097